dc.contributor.author | Bourke, JH | en_US |
dc.contributor.author | Wall, MB | en_US |
dc.date.accessioned | 2017-02-14T11:16:34Z | |
dc.date.available | 2015-04-23 | en_US |
dc.date.issued | 2015-05-07 | en_US |
dc.date.submitted | 2017-02-10T16:12:22.487Z | |
dc.identifier.issn | 1662-453X | en_US |
dc.identifier.other | ARTN 167 | en_US |
dc.identifier.other | ARTN 167 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/19380 | |
dc.description.sponsorship | Dr. Bourke is supported by a strategic research grant from Barts Charity (470/1700). | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | FRONTIERS IN NEUROSCIENCE | en_US |
dc.rights | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | |
dc.subject | pharmocological MRI | en_US |
dc.subject | pharmaco fMRI | en_US |
dc.subject | phMRI | en_US |
dc.subject | methodology | en_US |
dc.subject | neuroscience | en_US |
dc.subject | cognitive neuroscience | en_US |
dc.subject | psychopharmacology | en_US |
dc.subject | phfMRI | en_US |
dc.title | phMRI: methodological considerations for mitigating potential confounding factors | en_US |
dc.type | Article | |
dc.rights.holder | © 2015 Bourke and Wall | |
dc.identifier.doi | 10.3389/fnins.2015.00167 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361979600001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 9 | en_US |